Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

被引:0
作者
Guangfu Hu
Guangxia Hu
Chengjiao Zhang
Xiaoyan Lin
Ming Shan
Yanmin Yu
Yongwei Lu
Ruijie Niu
Hui Ye
Cheng Wang
Cheng Xu
机构
[1] Affiliated to Shanghai Jiao Tong University School of Medicine,Department of Breast Surgery, Huangpu Branch, Shanghai Ninth People’s Hospital
[2] Affiliated to First Shandong Medical University,Department of Pathology, Binzhong People’s Hospital
[3] Shanghai Jiao Tong University School of Medicine,Department of Psychological Measurement, Shanghai Mental Health Center
[4] Tongji University School of Medicine,Department of Breast Surgery, Yangpu Hospital
来源
BMC Cancer | / 20卷
关键词
Adjuvant chemotherapy; Breast cancer; Invasive lobular carcinoma; Hormone receptor-positive;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 370 条
[1]  
Frank GA(2013)WHO classification of tumors of the breast, 2012 Arkh Patol 75 53-63
[2]  
Danilova NV(2008)Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast Cancer study group clinical trials J Clin Oncol 26 3006-3014
[3]  
Andreeva I(2010)Lobular breast carcinoma and its variants Semin Diagn Pathol 27 49-61
[4]  
Nefedova NA(2010)Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast Am J Surg Pathol 34 1472-1479
[5]  
Pestalozzi BC(1995)Tumor biology of infiltrating lobular carcinoma. Implications for management Ann Surg 222 549-559
[6]  
Zahrieh D(2015)Comprehensive molecular portraits of invasive lobular breast Cancer Cell 163 506-519
[7]  
Mallon E(2017)Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma PLoS One 12 12-836
[8]  
Gusterson BA(2015)Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics Breast Cancer Res 17 827-57
[9]  
Price KN(2012)Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics Breast Cancer Res Treat 131 51-509
[10]  
Gelber RD(2016)Differences in response and surgical management with Neoadjuvant chemotherapy in invasive lobular versus ductal breast Cancer Ann Surg Oncol 23 505-2865